Literature DB >> 7910610

Assessment of proliferating-cell nuclear antigen immunostaining in soft-tissue tumours: relationship to histological grade and mitotic activity.

P Korkolopoulou1, P Christodoulou, A Papanikolaou, A Tsenga, E Thomas-Tsagli.   

Abstract

The proliferative activity in 70 cases of soft-tissue tumours was estimated immunohistochemically using the monoclonal antibody PC-10, which recognizes proliferating-cell nuclear antigen (PCNA) in paraffin sections. The PCNA index (i.e. the percentage of positive neoplastic nuclei) and to a lesser degree the PCNA count (i.e. the number of positive neoplastic nuclei per ten high-power fields) positively correlated with the malignancy grade (PCNA index: P < 0.001; PCNA count: P < 0.01). However, the range of values of PCNA index and PCNA count was similar between benign and grade I tumours. A statistically significant positive correlation was also established between PCNA index and PCNA count on the one hand and mitotic count on the other, but the correlation coefficient was low (r = 0.351, P < 0.01, and r = 0.290, P < 0.05 respectively). These results indicate that PCNA immunostaining may successfully be used as an adjunct to the conventional histopathological parameters in assessing the malignancy grade in soft-tissue tumours although it is of limited value in distinguishing between benign and grade I tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910610     DOI: 10.1007/bf01240137

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  A clinical and pathological staging system for soft tissue sarcomas.

Authors:  W O Russell; J Cohen; F Enzinger; S I Hajdu; H Heise; R G Martin; W Meissner; W T Miller; R L Schmitz; H D Suit
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

Review 2.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

3.  The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis.

Authors:  A L Woods; P A Hall; N A Shepherd; A M Hanby; N H Waseem; D P Lane; D A Levison
Journal:  Histopathology       Date:  1991-07       Impact factor: 5.087

4.  Prognostic value of proliferating cell nuclear antigen in gastric carcinoma.

Authors:  S Jain; M I Filipe; P A Hall; N Waseem; D P Lane; D A Levison
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

5.  Proliferating cell nuclear antigen (PCNA) in medullary thyroid carcinoma.

Authors:  A Skopelitou; P Korkolopoulou; A Papanikolaou; M Hadjiyannakis
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Identity of the proliferating cell nuclear antigen and cyclin.

Authors:  M B Mathews; R M Bernstein; B R Franza; J I Garrels
Journal:  Nature       Date:  1984 May 24-30       Impact factor: 49.962

7.  The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.

Authors:  J Costa; R A Wesley; E Glatstein; S A Rosenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

8.  Histopathological grading in soft-tissue tumours. Relation to survival in 261 surgically treated patients.

Authors:  O Myhre-Jensen; S Kaae; E H Madsen; O Sneppen
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1983-03

9.  Multivariate analysis for histologic prognostic factors in soft tissue sarcomas.

Authors:  M Tsujimoto; K Aozasa; T Ueda; Y Morimura; Y Komatsubara; T Doi
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

10.  Prognostic significance of Ki-67 reactivity in soft tissue sarcomas.

Authors:  T Ueda; K Aozasa; M Tsujimoto; M Ohsawa; A Uchida; Y Aoki; K Ono; K Matsumoto
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.